middle.news
How Clarity’s Cu-SAR-bisPSMA Is Changing Prostate Cancer Detection Ahead of EAU 2026
10:22am on Wednesday 24th of December, 2025 AEDT
•
Healthcare
Read Story
How Clarity’s Cu-SAR-bisPSMA Is Changing Prostate Cancer Detection Ahead of EAU 2026
10:22am on Wednesday 24th of December, 2025 AEDT
Key Points
Co-PSMA Phase II trial met primary endpoint with Cu-SAR-bisPSMA outperforming standard Ga-PSMA-11 PET/CT
Trial focused on patients with low PSA levels post-radical prostatectomy eligible for salvage therapy
Abstract accepted for oral presentation at Europe’s largest urology conference in March 2026
Cu-SAR-bisPSMA benefits from proprietary SAR technology preventing copper leakage
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Clarity Pharmaceuticals (ASX:CU6)
OPEN ARTICLE